NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyAccelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
About This Grant
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.
Grant Summary
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) is a National Institutes of Health grant providing funding that varies by award for municipality, school district, university. Applications are due 2027-02-11 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 800+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Not stated by funder
2027-02-11
- 1Confirm your organization is eligible for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed): Frequently Asked Questions
Who is eligible for the Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)?
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) is offered by National Institutes of Health. The listing names these applicant types: municipality, school district, university, tribal government, nonprofit, small business. It is open to organizations nationwide unless the funder specifies otherwise. The funder's eligibility section is the authority, so confirm your organization type, location, and the population or project served against it before applying.
How much funding does the Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) provide?
National Institutes of Health does not publish a set award amount for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed), so award sizes vary. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs, and confirm the expected range with the funder.
When is the Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) deadline?
Applications for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) are due 2027-02-11 (open). Because deadlines can change, verify the date with the funder, National Institutes of Health, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)?
To apply for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.
Browse More Grants
Related Grants
State Veterans Home Construction Grant Program
Construction of State Home Facilities — up to $275M
Advancing Global Health
Bureau of Global Health Security and Diplomacy — up to $250M
Title X Family Planning Services Grants
Office of the Assistant Secretary for Health — up to $22M
Occupational Safety and Health Education and Research Centers (T42)
Centers for Disease Control and Prevention - ERA — up to $9M
BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed)
National Institutes of Health — up to $8M
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
National Institutes of Health — up to $8M